Hormone receptor-positive breast cancer

This phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…

This study tests a combination of two drugs—alpelisib (a targeted therapy) and fulvestrant (a hormone blocker)—in Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA mutation. The cancer must have worsened after prior…

This study tests a combination of two experimental drugs (LEE011 and BYL719) plus a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the triple combination can better control the cancer. Participant…

This phase 3 study tests whether adding alpelisib (a targeted pill) to fulvestrant (a hormone-blocking shot) can slow cancer growth in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. Participants must have already tr…

This phase II study tests whether adding alpelisib (a targeted pill) to standard fulvestrant (a hormone-blocking shot) can delay cancer growth in Chinese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that has wors…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

Researchers are testing whether adding pyrotinib, an oral drug that targets HER2-family proteins, to standard chemotherapy helps shrink HER2-low, hormone receptor-positive breast cancer before surgery. The trial enrolls about 48 women with early or locally advanced disease. Every…

Researchers are testing whether adding apatinib, a drug that blocks blood vessel growth, to a CDK4/6 inhibitor and hormone therapy helps control HR+/HER2- advanced breast cancer. The trial enrolls women aged 18 to 75 with confirmed HR-positive, HER2-negative invasive breast cance…

This early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…

Researchers are testing two experimental oral drugs, PF-07220060 and PF-07104091, combined with standard hormone therapy in people with advanced breast cancer and other solid tumors. The trial has two parts: one that finds the safest dose and another that tests the combination in…

This Phase 3 study compares a new daily pill, giredestrant, against the standard shot fulvestrant, both given alongside a CDK4/6 inhibitor, in about 1,050 people with ER+/HER2- advanced breast cancer that has become resistant to prior hormone therapy. The goal is to see if girede…

This phase II trial studies whether giving radiation therapy before surgery can shrink hormone receptor-positive, HER2-negative breast tumors. About 25 participants will receive radiation followed by breast surgery. The goal is to see if this approach reduces the amount of normal…

This study tests whether adding the experimental drug inavolisib to two standard treatments (palbociclib and fulvestrant) can slow cancer growth in people with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer. About 325 parti…

This phase 2 trial tests three drug combinations—fulvestrant alone, fulvestrant plus palbociclib, and fulvestrant plus palbociclib plus avelumab—in 220 people with ER+/HER2- metastatic breast cancer that has progressed after prior CDK inhibitor therapy. The goal is to see which c…

This early-phase trial is testing a new combination of drugs for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. The experimental treatment includes a radioactive drug (lutetium NeoB) that targets cancer cells, plu…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study …

This large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…

This study tests a system called CONCURxP that uses a smart pill dispenser (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills as prescribed. About 410 patients will be split into two groups: one gets the full system…

This phase 3 trial tests whether adding the drug palbociclib to standard hormone therapy can help prevent breast cancer from coming back in people with a specific type of breast cancer (HR+/HER2-). About 405 participants who had surgery for a local or regional recurrence will rec…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study looks at the long-term safety of a drug called TOL2506, which suppresses ovarian function, in people with hormone receptor-positive (HR+) breast cancer. It includes premenopausal women and men who already completed a previous study. Participants will take TOL2506 along…

This phase 1 trial tests whether a personalized aerobic exercise program, including supervised walking sessions done remotely, can be safely added to the usual first-line hormone therapy for metastatic breast cancer. Researchers want to see if exercise helps delay the development…

This early-stage trial tests an oral drug called RGT-419B in Chinese patients with advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative, as well as other advanced solid tumors. The main goal is to see if the drug is safe and tolerable, and to f…

This early-stage study tests a new drug (H3B-6545) combined with an existing drug (palbociclib) in women with advanced or metastatic ER+ HER2- breast cancer. The main goal is to find the safest dose and understand side effects. About 31 women who have already tried other treatmen…

This study tested a new oral drug, AZD9833, against a standard injected treatment (fulvestrant) in 240 women with advanced ER-positive, HER2-negative breast cancer. The main goal was to see how long the cancer stayed under control. Results from one dose group were limited because…

This Phase 3 trial is testing an experimental drug called Dato-DXd against standard chemotherapy in 732 people with advanced HR-positive, HER2-negative breast cancer. Participants have already tried one or two prior chemotherapies. The study aims to see if Dato-DXd can slow cance…

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This phase 2 trial tests a new drug called PF-07220060 combined with fulvestrant against standard treatments in 333 adults with HR-positive, HER2-negative advanced or metastatic breast cancer that has worsened after prior CDK4/6 inhibitor therapy. Half receive the experimental co…

This phase II trial is testing whether giving the drug palbociclib (Ibrance) together with hormone therapy (letrozole, plus goserelin for premenopausal women) before surgery can shrink early-stage hormone receptor-positive, HER2-negative breast tumors. The study enrolls 51 patien…

This early-stage trial is testing whether adding an experimental drug called Ipatasertib to standard hormone therapy can help control metastatic hormone receptor positive breast cancer. The study involves 77 women whose cancer has spread and is no longer responding to usual treat…

This study tests whether adding the targeted drug pyrotinib to standard chemotherapy can better shrink tumors before surgery in people with a common type of early breast cancer (HR-positive, HER2-low). About 160 adults with high-risk, early-stage breast cancer will be randomly as…

This early-phase trial tests a new drug called AZD9833, alone or with other medicines, in women with a specific type of advanced breast cancer (ER-positive, HER2-negative). The main goals are to check safety and find the right dose. About 396 women will take part. This is not a c…

This early study tests whether combining a special immune-boosting vaccine (DC1) with the drug elacestrant is safe and doable for people with a common type of advanced breast cancer (HR+ HER2-). About 18 participants will receive the treatment for 8 weeks. The goal is to see if t…

This phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…

This study tests whether adding the experimental drug capivasertib to standard hormone therapy and CDK4/6 inhibitors can delay cancer growth in people with advanced HR+/HER2- breast cancer that cannot be removed by surgery or has spread. About 895 adults whose cancer has not resp…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This study tests whether a very low-carb (ketogenic) diet, a low-carb diet, or the diabetes drug canagliflozin can prevent high blood sugar and possibly make standard cancer therapy more effective. It involves 15 people with advanced, hormone-receptor-positive breast cancer that …

This Phase 3 trial tests whether an experimental drug called SIM0270 combined with everolimus works better than standard treatments for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after CDK4/6 inhibitor therapy. About 460 participants will be rand…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study looks at whether high-dose vitamin D and a home exercise program (walking and strength training) can help prevent bone loss in women being treated for breast cancer. About 191 postmenopausal women with early-stage breast cancer will take either vitamin D or a placebo, …

This phase 3 trial tests whether adding entinostat to the hormone therapy exemestane helps control advanced hormone receptor-positive breast cancer better than exemestane alone. About 600 patients with locally advanced or metastatic breast cancer are participating. The study meas…

This study looks at whether using ultrasound before surgery can help identify women with early-stage HR+/HER2- breast cancer who have only a few affected lymph nodes. If so, they may be able to have a less invasive sentinel lymph node biopsy instead of a more extensive axillary l…

This early-stage trial tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-po…

This pilot study tests two oral drugs, anastrozole and palbociclib, in postmenopausal women with a common type of metastatic breast cancer (HR+/HER2-). The drugs are given either as the first treatment or as maintenance after chemotherapy. The main goal is to see if the combinati…

This phase II trial is testing whether a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and fulvestrant (a hormone blocker)—can slow or stop the growth of a specific type of advanced breast cancer. The study enrolls people with ER-positiv…

This study tests a new drug called BL-B01D1 against standard chemotherapy in about 383 people with advanced HR+HER2- breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth or improve survival. Participants ar…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer getting worse. About 340 participants who have already tried hormone therapy wil…

This phase 3 trial tests whether a combination of the targeted drug abemaciclib plus hormone therapy works as well as standard chemotherapy for women with ER+ HER2- breast cancer that has spread to the liver, lungs, or other organs. About 180 participants will be randomly assigne…

This early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…

This phase 3 trial tests whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor can delay cancer progression better than staying on standard aromatase inhibitor therapy in people with HR+/HER2- metastatic breast cancer who have an ESR1 mutation. About 315 particip…

This phase II study is testing a combination of three drugs—lenvatinib, pembrolizumab, and letrozole—in people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy. The goal is to see if this combination can …

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study is for people with a certain type of breast cancer (HER2-negative) that has spread to lymph nodes. It tests giving a mix of chemotherapy, an immunotherapy drug (pembrolizumab), and different doses of radiation before surgery. The goal is to see if this approach helps t…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study is for people with a high-risk type of breast cancer (ER+/HER2-) who have finished initial treatment but still face a chance of the cancer coming back. Researchers will use a simple blood test to look for tiny bits of tumor DNA. If found, participants will be randomly …

This clinical trial is testing whether combining two drugs, palbociclib and bicalutamide, is safe and effective for people with a specific type of metastatic breast cancer that is triple-negative and androgen receptor positive. The study involves women whose cancer has spread and…

This study tests a combination of two drugs, capivasertib and fulvestrant, in 101 people with a specific type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and a CDK4/6 inhibitor. The goal is to see how long it takes before the next cancer t…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any pa…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase 2 trial investigates whether a program of regular walking and a plant-based diet can lower aromatase levels in overweight postmenopausal women with hormone receptor-positive breast cancer who are already taking an aromatase inhibitor. Participants are randomly assigned…

This study tests an experimental drug called enfortumab vedotin in 329 adults with advanced solid tumors that have spread. The main goal is to see if the drug shrinks tumors. Researchers also check how long the effect lasts and monitor side effects. Some participants also receive…

This study tested whether adding the drug palbociclib for two years to standard hormone therapy (taken for at least five years) helps prevent breast cancer from coming back in people with early-stage HR+/HER2- breast cancer. About 5,800 participants with stage II or III cancer to…

This study tests two drugs, olaparib and pembrolizumab, given before standard surgery for people with triple-negative or hormone receptor-positive HER2-negative breast cancer who have specific gene mutations. The goal is to see if the combination can shrink tumors enough to impro…

This study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…

This early-phase trial tests a new drug called HRS8807, alone or with another drug SHR6390, in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to find safe doses and check for side effects. Participants have already t…

This phase 2 trial tests whether adding alpelisib to continued fulvestrant can help people with advanced, hormone-receptor-positive, HER2-negative breast cancer that has a PIK3CA mutation. Participants have already seen their cancer progress while on fulvestrant. The study aims t…

This phase 2 trial is testing a higher dose (500 mg) of the hormone therapy fulvestrant (Faslodex) as a first treatment for postmenopausal women with hormone receptor positive metastatic breast cancer. The study aims to see if this higher dose improves clinical benefit rates comp…

This study looks at whether adding surgery or radiation to a standard drug combination (palbociclib plus letrozole) can help people with newly diagnosed stage IV ER+/HER2- breast cancer live longer. About 200 women with cancer that has spread beyond the breast will receive the dr…

This study looks at whether adding a CDK4/6 inhibitor (a targeted drug) to hormone therapy earlier or later works better for women with advanced hormone-receptor-positive breast cancer. About 1,050 women will receive either the drug combo first followed by another hormone therapy…

This study tests a new drug (PF-07220060) plus letrozole against standard treatments for people with HR-positive, HER2-negative advanced or metastatic breast cancer who haven't had prior therapy for advanced disease. About 1,035 adults will be randomly assigned to either the new …

This study tests if a combination of ribociclib (a targeted pill) and hormone therapy works better than standard chemotherapy for women with a common type of early breast cancer (HR+/HER2-). About 1,684 women with intermediate-risk disease are taking part. The goal is to see whic…

This Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…

This study tests two oral medications, vepdegestrant and samuraciclib, taken daily at home by adults with advanced or metastatic ER+ breast cancer that no longer responds to standard treatments. The goal is to see if the combination is safe and can shrink or control the cancer. P…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This phase 3 trial tests whether adding capivasertib to standard fulvestrant therapy can slow cancer growth in people with advanced HR+/HER2- breast cancer. About 818 participants whose cancer worsened after hormone therapy will receive either the combination or a placebo plus fu…

This early-phase trial tests a new oral drug, SH3765, combined with the injectable hormone therapy fulvestrant in 30 women with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The main goals are to check safety, find the best dose, and see if the combina…

This phase 3 study tests whether adding the targeted drug abemaciclib to standard hormone therapy helps prevent breast cancer from returning in people with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to lymph nodes. Over 5,600 pa…

This Phase III trial tests whether adding the experimental drug TQB3616 to standard hormone therapy can help prevent breast cancer from returning in women with HR-positive, HER2-negative breast cancer after surgery. About 1,946 women will receive either TQB3616 or a placebo, plus…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…

This Phase 2 study tests a drug called zelenectide pevedotin in 66 people with advanced breast cancer that has a specific gene change (NECTIN4 amplification). The study includes two groups: one with hormone receptor-positive/HER2-negative cancer and one with triple-negative breas…

This phase 3 trial tests whether adding the experimental drug ipatasertib to standard hormone therapy (fulvestrant) can slow the growth of advanced ER-positive, HER2-negative breast cancer. The study enrolls 250 postmenopausal women whose cancer worsened after initial treatment w…

This early-phase study tests a new immune-boosting drug (DPX-Survivac) combined with hormone therapy, with or without low-dose radiation or chemotherapy, in women with hormone receptor-positive, HER2-negative breast cancer. The main goal is to check safety before standard surgery…

This phase 2 study tests a new drug (TQB3616) combined with hormone therapy for people with a common type of breast cancer (HR-positive, HER2-negative) that has returned or spread and no longer responds to a standard class of drugs called CDK4/6 inhibitors. The trial enrolls 33 a…

This phase 3 trial tests whether adding afuresertib (a targeted drug) to fulvestrant (a standard hormone therapy) can help control advanced HR+/HER2- breast cancer that has stopped responding to other treatments. The study includes 256 adults with specific genetic changes (PIK3CA…

This Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…

This study compares the brand-name drug Ibrance (palbociclib) with a local generic version in 100 Iraqi women with stage IV hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works just as well and is as safe as the brand. Patients take the …

This study tests a drug called fluzoparib, either alone or with another drug called camrelizumab, in people with a specific type of advanced breast cancer (HRD-positive, HER2-negative). The goal is to see if these treatments can shrink tumors or slow the cancer's growth. About 80…

This phase 2 trial is testing whether adding the targeted drug dalpiciclib to standard hormone therapy (letrozole) before surgery can improve outcomes for women with HR+/HER2- early-stage breast cancer. The study enrolls 100 women aged 18-70 whose tumors have a high genetic risk …

This phase 2 trial tests whether adding ribociclib to letrozole before surgery helps more women with ER-positive, HER2-negative early breast cancer achieve a low-risk score (PEPI 0) compared to letrozole alone. About 121 postmenopausal women with stage II or III breast cancer wil…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…

This study tests an experimental oral drug, MRT-2359, in adults with certain advanced cancers, including lung cancer, lymphoma, and other solid tumors driven by MYC genes. The first part finds the safest dose; the second part checks if the drug shrinks tumors. About 174 participa…

This study tests two oral drugs, vepdegestrant and PF-07220060, in people with advanced or metastatic ER+/HER2- breast cancer that has stopped responding to prior treatments. The goal is to see if the combination is safe and can shrink tumors. Participants take the pills at home …

This phase 3 study tests a drug called sacituzumab govitecan (Trodelvy) against standard chemotherapy in 331 Asian patients with HR+/HER2- metastatic breast cancer who have already tried at least two prior chemotherapies. The goal is to see if the new drug can delay cancer growth…

This Phase 3 trial tests a new experimental drug, vepdegestrant, combined with palbociclib against the standard treatment (letrozole plus palbociclib) for people with advanced ER+/HER2- breast cancer that has not been treated before. The study aims to see if the new combination w…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This Phase 3 trial is testing a new drug called gedatolisib combined with fulvestrant, with or without palbociclib, in about 700 people with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The goal is to see if this combination can slow cancer growth bet…

This phase 3 trial tested whether adding the drug everolimus to standard hormone therapy helps prevent breast cancer from returning in nearly 2,000 patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. Participants received either hormone therapy plus e…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapies (anastrozole, letrozole, or fulvestrant) can help slow cancer growth in postmenopausal women with a common type of advanced breast cancer (HR+, HER2-). About 463 women participated, and the…

This phase 2 study tests the drug abemaciclib, either alone or with tamoxifen, in 234 women with a specific type of advanced breast cancer (HR+, HER2-). The goal is to see if these treatments can slow cancer growth in patients whose disease has progressed after prior therapies. P…

This phase 3 trial tests whether adding abemaciclib to standard hormone therapy (anastrozole or letrozole) can slow cancer growth in postmenopausal women with HR+ HER2- breast cancer that has spread or returned. About 493 women participated, receiving either the drug combination …

This study tests whether a combination of two targeted pills (fluorizoparib and apatinib) works better than standard chemotherapy for people with a specific genetic type of advanced breast cancer (HRD-positive, HER2-negative). About 200 participants will be randomly assigned to e…

This early-phase trial tests the safety of combining the targeted drug abemaciclib with various other breast cancer treatments (like letrozole, tamoxifen, or trastuzumab) in 198 people whose breast cancer has spread. The goal is to find safe combinations that may help control the…

This early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…

This study tests whether adding abemaciclib to fulvestrant can slow or stop the growth of a common type of advanced breast cancer (HR+, HER2-) that has worsened after initial treatment. About 368 participants will receive either the drug combo or a placebo plus fulvestrant. The g…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a common type of advanced breast cancer (HR+/HER2-). About 110 participants receive either the combination or sacituzumab alone. The goal is to see if the combo delays cancer growt…

This phase 3 study tests a 3-month injection (TOL2506) to temporarily stop ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The goal is to see if it works well with hormone therapy (tamoxifen or aromatase inhibitors) to control the cancer. About 250 …

This study tests whether adding the drug pyrotinib to standard chemotherapy before surgery can improve outcomes for women with stage II to III hormone receptor-positive, HER2-negative breast cancer that also has high levels of the HER4 protein. About 140 participants will receive…

This phase 3 trial tests whether adding an experimental drug (TQB3616) to standard hormone therapy (fulvestrant) can delay cancer growth in people with HR-positive, HER2-negative advanced breast cancer. About 432 participants will receive either the combination or a placebo plus …

This phase 2 trial tests whether adding the targeted drug alpelisib to ongoing hormone therapy can help people with a specific genetic mutation (PIK3CA) in advanced breast cancer that has stopped responding to hormone therapy alone. About 44 participants will take daily alpelisib…

This study aimed to see if the drug capivasertib could clear cancer DNA from the blood of women with ER-positive breast cancer who had finished initial treatment. The goal was to prevent the cancer from coming back or spreading. However, the study was withdrawn before any partici…

This study tests whether adding a targeted drug (PD 0332991) to standard hormone therapy (anastrozole) before surgery can better stop breast cancer cell growth in women with early-stage ER+ HER2- breast cancer. About 84 women with stage 2 or 3 disease will receive the combination…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 adults with triple-n…

This early-stage trial tests a new drug called OP-1250 combined with an approved targeted therapy, palbociclib, in 60 adults with advanced or metastatic HR-positive, HER2-negative breast cancer. The goal is to find the safest dose and see if the combination can slow tumor growth.…

This phase 3 trial studies whether adding the drug abemaciclib (Verzenios) to standard hormone therapy helps prevent breast cancer from coming back in 1,260 women with high-risk, HR+/HER2- early breast cancer. Participants have already completed initial treatments like surgery or…

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This phase 3 study tested whether adding the drug abemaciclib to standard hormone therapy (fulvestrant) helps women with a common type of advanced breast cancer (HR+, HER2-) live longer without their cancer growing. About 669 women took part, receiving either the combination or f…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…

This phase 3 study tests whether the drug sacituzumab govitecan (Trodelvy) can help people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer growing. About 654 participants will receive either the new drug or one of three standard chemother…

This study tests a new injectable form of leuprolide in 211 premenopausal women with hormone-positive breast cancer. The goal is to see if it can safely keep estrogen at postmenopausal levels for nearly a year, which helps control cancer growth. Participants receive the drug and …

This early-stage trial tests an experimental oral drug called AC699 in 100 adults with a common type of advanced breast cancer (ER+/HER2-). The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tumors. Par…

This study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 …

This phase 2 trial tests whether a combination of two drugs, ribociclib and letrozole, can replace standard chemotherapy for postmenopausal women with a common type of breast cancer (hormone receptor positive, HER2 negative). The study involves 100 participants who will receive e…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This study is testing an artificial intelligence (AI) tool that analyzes digitized images of tumor tissue from 2,200 women with ER-positive, HER2-negative early breast cancer. The AI aims to predict the risk of cancer spreading to distant parts of the body. Researchers will compa…

This study looks at whether women aged 65 and older with early-stage, estrogen-positive breast cancer can safely have a lumpectomy without also removing and testing nearby lymph nodes (sentinel node biopsy). The goal is to see if skipping this extra step leads to cancer coming ba…

This study looks at whether starting hormone therapy every other day for one month, then switching to daily, helps women with early breast cancer take their medication as prescribed. About 240 participants will be randomly assigned to either the standard daily dose or the gradual…

This study tests a drug called elinzanetant to see if it can reduce hot flashes in women with hormone-receptor positive breast cancer who are on hormone-blocking therapy. About 474 women will take either the drug or a placebo for 12 weeks, then all will receive the drug for up to…

This phase 2 trial is testing whether gradually increasing the dose of abemaciclib (a targeted cancer drug) can reduce side effects like diarrhea and help patients stick with treatment. It involves 90 people with early-stage, hormone receptor-positive, HER2-negative breast cancer…

This study tests fezolinetant, a non-hormonal drug, for treating hot flashes in women with hormone-positive breast cancer who are on hormone therapy. About 984 women will take either fezolinetant or a placebo daily for a year. The goal is to see if fezolinetant reduces the number…

This study tests whether regular symptom check-ins via text or email, plus educational materials, can help young women with early-stage breast cancer stay on their hormone therapy. Many women stop treatment early due to side effects. The trial involves 565 women and compares symp…

This trial tests whether an AI-based management platform, called 'Zhiliao Doctor,' can reduce anxiety and depression in 300 breast cancer patients taking CDK4/6 inhibitors at home. Participants are randomly assigned to standard care, the AI platform, or personalized follow-up cal…

This study tests whether text message reminders and phone counseling help women with early-stage breast cancer take their daily hormone therapy pills as prescribed. About 1,167 women will be split into groups: some get usual care, others get texts and/or motivational interviewing…

This study follows 25 women with advanced breast cancer to understand why the drug palbociclib stops working over time. Researchers collect blood and tumor samples before and after the cancer progresses to look for genetic and chemical changes. The goal is not to treat the diseas…

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study is investigating whether genetic changes in tumor tissue and blood can predict how well people with hormone receptor-positive metastatic breast cancer respond to a combination of endocrine therapy and palbociclib. Researchers will collect tumor samples and blood from p…

This study combines MRI scans with detailed genetic and molecular analysis (multiomics) to improve how luminal breast cancer is classified and treated. Researchers aim to develop models that predict treatment resistance, recurrence, and spread, helping doctors choose the most eff…

This study looks at how the drug ribociclib is actually used in everyday medical practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will analyze medical records from thousands of patients to see who gets the drug, how long they take it, and wha…

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study follows over 1,400 patients in Germany and Austria with HR+/HER2- advanced breast cancer who are receiving standard first-line treatment with palbociclib plus hormone therapy. Researchers are collecting real-world data on how long the cancer stays controlled and overal…

This study follows 329 older patients (65 years and up) with HR+HER2- advanced breast cancer who are taking ribociclib combined with endocrine therapy as their first or second treatment. Researchers are tracking quality of life, treatment effectiveness, and safety in real-world c…

This study watches how women with a certain type of advanced breast cancer are treated with the drug ribociclib in everyday medical practice in France. It does not give any new treatment but simply collects information on dosing, side effects, and how long the drug works. About 1…

This study looks at whether a gene test called Prosigna can help doctors choose the best treatment for women with a common type of breast cancer (HR+/HER2-) before surgery. About 60 women will have their treatment decisions recorded before and after the test results. The goal is …

This study collects tumor and blood samples from 241 women with HR+/HER2- advanced breast cancer before and after treatment with ribociclib (Kisqali) plus hormone therapy. Researchers will analyze DNA and RNA changes to find markers that predict who responds well and who develops…

This study follows 376 people with HR+HER2- advanced breast cancer who are taking ribociclib (Risarg) plus endocrine therapy or chemotherapy as part of their routine care in Russia. The goal is to see how long patients stay on treatment before stopping for any reason. Since this …

This was an observational study designed to collect medical data from people with HR+/HER2- advanced breast cancer during routine care. The goal was to track treatment effectiveness and side effects in real-world settings. However, the study was withdrawn before enrolling any par…

This study looks at how Palbociclib and other CDK4/6 inhibitors are actually used in patients with a common type of advanced breast cancer (HR+/HER2-). Researchers will analyze anonymous medical records from routine care to see how long patients stay on treatment and whether it d…